Э К Возный

3.2k total citations · 2 hit papers
6 papers, 2.5k citations indexed

About

Э К Возный is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Э К Возный has authored 6 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 1 paper in Surgery. Recurrent topics in Э К Возный's work include Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Cancer Treatment and Pharmacology (2 papers). Э К Возный is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Cancer Treatment and Pharmacology (2 papers). Э К Возный collaborates with scholars based in Portugal, Poland and Russia. Э К Возный's co-authors include Sergei Tjulandin, Vladimir Moiseyenko, Yee Chao, M Fodor, C. Boni, Alejandro Majlis, Adriano Rodrigues, Manuel Constenla, Jaffer A. Ajani and Eric Van Cutsem and has published in prestigious journals such as Journal of Clinical Oncology and PubMed.

In The Last Decade

Э К Возный

6 papers receiving 2.4k citations

Hit Papers

Phase III Study of Doceta... 2005 2026 2012 2019 2006 2005 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
    2006 1.5k citations Eric Van Cutsem, Vladimir Moiseyenko et al. Journal of Clinical Oncology profile →
  2. Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study
    2005 505 citations Brian Leyland‐Jones, Semiglazov Vf et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Э К Возный Portugal 5 1.6k 1.3k 784 568 440 6 2.5k
Jin Sik Min South Korea 24 855 0.5× 874 0.7× 922 1.2× 363 0.6× 41 0.1× 70 1.9k
Jae Moon Bae South Korea 31 2.7k 1.6× 987 0.8× 1.4k 1.8× 1.3k 2.3× 96 0.2× 132 3.9k
Élie Oussoultzoglou France 31 921 0.6× 2.1k 1.7× 1.8k 2.3× 63 0.1× 133 0.3× 68 3.3k
Suee Lee South Korea 23 787 0.5× 1.3k 1.1× 542 0.7× 108 0.2× 76 0.2× 84 2.2k
J. Wils Netherlands 20 1.1k 0.7× 1.7k 1.3× 760 1.0× 286 0.5× 49 0.1× 48 2.2k
Manuel Constenla Spain 19 2.2k 1.4× 2.0k 1.6× 909 1.2× 591 1.0× 40 0.1× 53 3.1k
Michael Fanucchi United States 15 809 0.5× 764 0.6× 124 0.2× 55 0.1× 248 0.6× 33 1.5k
Wilfried Grothe Germany 11 1.5k 0.9× 1.0k 0.8× 726 0.9× 498 0.9× 39 0.1× 21 2.3k
Albrecht Kretzschmar Germany 21 1.5k 0.9× 1.6k 1.2× 721 0.9× 388 0.7× 30 0.1× 71 2.5k
A. Lecesne France 15 1.3k 0.8× 563 0.4× 571 0.7× 1.1k 1.9× 227 0.5× 39 2.1k

Countries citing papers authored by Э К Возный

Since Specialization
Citations

This map shows the geographic impact of Э К Возный's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Э К Возный with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Э К Возный more than expected).

Fields of papers citing papers by Э К Возный

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Э К Возный. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Э К Возный. The network helps show where Э К Возный may publish in the future.

Co-authorship network of co-authors of Э К Возный

This figure shows the co-authorship network connecting the top 25 collaborators of Э К Возный. A scholar is included among the top collaborators of Э К Возный based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Э К Возный. Э К Возный is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Ajani, Jaffer A., Vladimir Moiseyenko, Sergei Tjulandin, et al.. (2007). Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. Journal of Clinical Oncology. 25(22). 3205–3209. 208 indexed citations
2.
Ajani, Jaffer A., Vladimir Moiseyenko, Sergei Tjulandin, et al.. (2007). Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. Journal of Clinical Oncology. 25(22). 3210–3216. 158 indexed citations
3.
Cutsem, Eric Van, Vladimir Moiseyenko, Sergei Tjulandin, et al.. (2006). Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. Journal of Clinical Oncology. 24(31). 4991–4997. 1480 indexed citations breakdown →
4.
Harvey, Vernon, Henning T. Mouridsen, Semiglazov Vf, et al.. (2006). Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. Journal of Clinical Oncology. 24(31). 4963–4970. 121 indexed citations
5.
Leyland‐Jones, Brian, Semiglazov Vf, Marek Pawlicki, et al.. (2005). Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study. Journal of Clinical Oncology. 23(25). 5960–5972. 505 indexed citations breakdown →
6.
Возный, Э К, et al.. (1974). [Comparative evaluation of the efficacy of fluorofur (Ftorafur) and 5-fluorouracil (5-ftouracil) in the treatment of breast cancer].. PubMed. 65(52). 2811–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jin Sik Min Breakdown of academic impact, for papers by Jae Moon Bae Breakdown of academic impact, for papers by Élie Oussoultzoglou Breakdown of academic impact, for papers by Suee Lee Breakdown of academic impact, for papers by J. Wils Breakdown of academic impact, for papers by Manuel Constenla Breakdown of academic impact, for papers by Michael Fanucchi Breakdown of academic impact, for papers by Wilfried Grothe Breakdown of academic impact, for papers by Albrecht Kretzschmar Breakdown of academic impact, for papers by A. Lecesne
Rankless by CCL
2026